Recurrent Malignant Pleural Effusion Management

<h3>Background</h3> Guidelines recommend early definitive management (indwelling pleural catheter, pleurodesis, decortication, or combination approach) for patients with symptomatic, rapidly recurrent malignant pleural effusion (MPE). This study evaluates health care utilization among patients who received early definitive management (EDM), defined as definitive management at first episode of rapidly recurrent MPE, compared with patients who do not (no early definitive management [NEDM]). <h3>Research Question</h3> What percentage of patients with rapidly recurrent symptomatic MPE receive guideline-consistent EDM and are there differences in care outcomes? <h3>Study Design and Methods</h3> This retrospective cohort study analyzed medical records from Dartmouth-Hitchcock Medical Center (a 500-bed primary teaching hospital) from 2018 to 2022. The cohort included patients with biopsy-proven MPE and rapid recurrence within 14 days of the initial thoracentesis, requiring a second pleural procedure. We compared the outcomes between patients who received EDM and those with NEDM. <h3>Results</h3> A total of 133 patients met the inclusion criteria: confirmed malignancy on initial thoracentesis and rapid recurrence requiring repeat pleural procedure within 14 days. Of these, 52 patients (39%) received EDM, whereas 81 (61%) underwent repeat thoracentesis or chest tube drainage (NEDM). Compared with patients with NEDM, patients with EDM had fewer total pleural procedures (2.08 vs 3.51; <i>P</i> < .01), a lower rate of MPE-related emergency department visits (events per patient; 0.23 vs 1.31; <i>P</i> < .01), and a lower rate of MPE-related hospitalizations (events per patient; 0.23 vs 0.99; <i>P</i> < .01). A cost analysis of MPE-related hospitalizations revealed substantially lower MPE-related hospitalization costs for patients with EDM compared with patients with NEDM ($9,857 vs $39,497 per patient). No significant differences in survival were observed (<i>P</i> = .80). <h3>Interpretation</h3> Less than one-half of eligible patients received guideline-consistent EDM for rapidly recurrent MPE. Those not receiving EDM required more health care resources, including pleural procedures, emergency department visits, and hospitalizations. These findings underscore the importance of EDM in reducing health care utilization and improving patient care outcomes.

Authors

Institutions

Publication Details

Journal
CHEST Pulmonary
Published
2025-11-05
DOI
https://doi.org/10.1016/j.chpulm.2025.100227
Primary Topic
Pleural and Pulmonary Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recurrent Malignant Pleural Effusion Management

Lara Goitein, David Feller‐Kopman, Elliot Backer, Phuong Nguyen et al.
CHEST Pulmonary
Pleural and Pulmonary Diseases
article

Recurrent Malignant Pleural Effusion Management

Lara Goitein, David Feller‐Kopman, Elliot Backer, Phuong Nguyen, Michael Wright
article en

Abstract

<h3>Background</h3> Guidelines recommend early definitive management (indwelling pleural catheter, pleurodesis, decortication, or combination approach) for patients with symptomatic, rapidly recurrent malignant pleural effusion (MPE). This study evaluates health care utilization among patients who received early definitive management (EDM), defined as definitive management at first episode of rapidly recurrent MPE, compared with patients who do not (no early definitive management [NEDM]). <h3>Research Question</h3> What percentage of patients with rapidly recurrent symptomatic MPE receive guideline-consistent EDM and are there differences in care outcomes? <h3>Study Design and Methods</h3> This retrospective cohort study analyzed medical records from Dartmouth-Hitchcock Medical Center (a 500-bed primary teaching hospital) from 2018 to 2022. The cohort included patients with biopsy-proven MPE and rapid recurrence within 14 days of the initial thoracentesis, requiring a second pleural procedure. We compared the outcomes between patients who received EDM and those with NEDM. <h3>Results</h3> A total of 133 patients met the inclusion criteria: confirmed malignancy on initial thoracentesis and rapid recurrence requiring repeat pleural procedure within 14 days. Of these, 52 patients (39%) received EDM, whereas 81 (61%) underwent repeat thoracentesis or chest tube drainage (NEDM). Compared with patients with NEDM, patients with EDM had fewer total pleural procedures (2.08 vs 3.51; <i>P</i> < .01), a lower rate of MPE-related emergency department visits (events per patient; 0.23 vs 1.31; <i>P</i> < .01), and a lower rate of MPE-related hospitalizations (events per patient; 0.23 vs 0.99; <i>P</i> < .01). A cost analysis of MPE-related hospitalizations revealed substantially lower MPE-related hospitalization costs for patients with EDM compared with patients with NEDM ($9,857 vs $39,497 per patient). No significant differences in survival were observed (<i>P</i> = .80). <h3>Interpretation</h3> Less than one-half of eligible patients received guideline-consistent EDM for rapidly recurrent MPE. Those not receiving EDM required more health care resources, including pleural procedures, emergency department visits, and hospitalizations. These findings underscore the importance of EDM in reducing health care utilization and improving patient care outcomes.

CHEST PulmonaryVol. 4(1)
Dartmouth–Hitchcock Medical Center (US), Beth Israel Deaconess Medical Center (US)
Openalex Percentile: Top 53%
Pleural and Pulmonary Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.